Angiogenesis—one of the hallmarks of cancer—has emerged as a valid therapeutic target in
oncology. The VEGF system represents a key mediator of tumor-initiated angiogenesis and …

The existence of factors that stimulate blood vessel growth, thereby recruiting a neovascular
supply to nourish a growing tumour, was postulated many decades ago, although the …

VEGF inhibitors are widely used as a therapy for tumors and intravascular neovascular
disorders, but limited and conflicting data regarding their relative biological potencies are …

Purpose: Angiogenesis, one of the hallmarks of cancer, has recently become the target of
therapeutic approaches in oncology. Among the complex system of pro-and antiangiogenic …

The development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer …

Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein
tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis …

Introduction: Angiogenesis was first proposed as a possible target for the treatment of
human cancer several decades ago. During recent years, the discovery of VEGF as the main …

Antiangiogenic therapies that target VEGF or its receptors have become a mainstay of
cancer therapy in multiple malignancies. However, the clinical efficacy of these agents is …

Background: Angiogenesis, involving the formation of new blood vessels from preexisting
vessels, caters an important biological phenomenon for the growth and development of …

Angiogenesis is the process by which new blood vessels are created from pre‐existing
vessels. It is essential for the growth and development of normal cells and tissues during …